Cell News and Research

RSS

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that it has been selected to participate in a $3.7 million National Institutes of Health (NIH) Grand Opportunities (GO) grant awarded to The Johns Hopkins University.

22 Oct 2009

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.

22 Oct 2009

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

Scientists at GE Global Research, and researchers at Eli Lilly and Company today announced a significant advancement in cancer research resulting from the two companies’ collaboration formed in October 2007.

22 Oct 2009

HIV stigma: a barrier for proper care

The feeling of stigmatization that people living with HIV often experience doesn't only exact a psychological toll -new UCLA research suggests it can also lead to quantifiably negative health outcomes.

22 Oct 2009

Autoimmune initiates steps to enhance shareholder value, retains Junewicz & Co. as its financial advisor

AutoImmune Inc. today announced that its Board of Directors has authorized the exploration of a full range of strategic alternatives available to the Company in order to enhance shareholder value. AutoImmune has retained Junewicz & Co. as its financial advisor for this evaluation process.

22 Oct 2009

New partnership to create Translational Orthopedic Research Program

The creation of the Translational Orthopedic Research Program (TORP), a new partnership of Van Andel Research Institute (VARI) and its affiliate the Translational Genomics Research Institute (TGen), Spectrum Health, Orthopaedic Associates of Michigan (OAM), and the Michigan State University (MSU) College of Human Medicine, was announced today by officials of the sponsoring organizations who gathered at Van Andel Institute for the World Osteoporosis Day Summit, a meeting spotlighting local osteoporosis efforts.

22 Oct 2009

NIH awards $3.7 million to Johns Hopkins scientists for research on stem cells developed from ALS patients' skin

Johns Hopkins scientists have been awarded a $3.7 million grant from the National Institutes of Health (NIH) to learn more about the nerve and muscle-wasting disease amyotrophic lateral sclerosis (ALS) using stem cells developed from ALS patients' skin. The award, given over a two-year span, will be shared with three other laboratories, including one at Harvard University and two at Columbia University.

22 Oct 2009

NIH awards $8 million to The Medical College of Wisconsin for heart research

The Medical College of Wisconsin has been awarded a five-year, $8 million, multi-investigator Program Project Grant (PPG) from the National Institutes of Health to understand how human pluripotent stem cells, defined as cells which if left to their own designs can develop into any of the more than 200 cell types in the human body, can be channeled to exclusively become heart muscle cells.

22 Oct 2009

Study paves way for the creation of a stem cell library

The study, led by the University of Edinburgh's MRC Centre for Regenerative Medicine, paves the way for the creation of a stem cell library that can be used for in vitro hepatic disease models.

21 Oct 2009

Certain molecules found to play an important role in regulating circadian rhythm: Study

Molecules that may hold the key to new ways to fight cancer and other diseases have been found to play an important role in regulating circadian rhythm, says Liheng Shi, a researcher in Texas A&M's Department of Veterinary Integrative Biosciences.

21 Oct 2009

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

Curis, Inc. , a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 8th Annual BIO Investor Forum at 4:30 p.m. PDT (7:30 p.m. EDT) on October 28, 2009, at the Palace Hotel in San Francisco, California.

21 Oct 2009

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), has verbally informed the Company at an oral meeting to anticipate a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) in early-stage, localized renal cell carcinoma (kidney cancer).

21 Oct 2009

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing Phase 2a trial of AGS-004, its personalized immunotherapy candidate. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden.

21 Oct 2009

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

21 Oct 2009

CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting

CombinatoRx, Incorporated today announced the results of a 12 month knee osteoarthritis (OA) Phase 2 extension trial for Synavive™ (CRx-102) at the American College of Rheumatology (ACR) 2009 Annual Meeting in Philadelphia. The data demonstrated that Synavive-treated subjects maintained efficacy levels throughout the 12 month extension trial.

21 Oct 2009

Novavax, Xcellerex enter into collaboration to accelerate the development of Novavax's 2009 H1N1 vaccine

Novavax, Inc. and Xcellerex, Inc. have entered into a strategic collaboration to accelerate the development of Novavax's vaccine manufacturing process to commercial scale and begin immediate production of Novavax's novel 2009 H1N1 influenza vaccine for potential commercial sale.

21 Oct 2009

Shire to file a Biologics License Application for REPLAGAL with the FDA

Shire plc, the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease, by the end of the year.

21 Oct 2009

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Gamida Cell Ltd. and Cellerix, S.A. announced today that the companies are collaborating on a feasibility study to evaluate the added value of combining the proprietary technologies of each.

21 Oct 2009

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.

21 Oct 2009

Professor secures grant for further research on immunotherapy strategies

Venuprasad K. Poojary, Ph.D., assistant professor at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, has secured a two-year federal grant for almost $1 million to further his research into creating more effective immunotherapy strategies for cancer treatment.

21 Oct 2009

Cell News and Research

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

HIV stigma: a barrier for proper care

Autoimmune initiates steps to enhance shareholder value, retains Junewicz & Co. as its financial advisor

New partnership to create Translational Orthopedic Research Program

NIH awards $3.7 million to Johns Hopkins scientists for research on stem cells developed from ALS patients' skin

NIH awards $8 million to The Medical College of Wisconsin for heart research

Study paves way for the creation of a stem cell library

Certain molecules found to play an important role in regulating circadian rhythm: Study

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting

Novavax, Xcellerex enter into collaboration to accelerate the development of Novavax's 2009 H1N1 vaccine

Shire to file a Biologics License Application for REPLAGAL with the FDA

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

Professor secures grant for further research on immunotherapy strategies

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News